Safety, tolerability, pharmacokinetics of single ascending dose and multiple ascending doses of CC-11050, food effect of CC-11050, and drug interaction of CC-11050 with isoniazid plus rifampin or isoniazid plus rifabutin: A phase I study

Trial Profile

Safety, tolerability, pharmacokinetics of single ascending dose and multiple ascending doses of CC-11050, food effect of CC-11050, and drug interaction of CC-11050 with isoniazid plus rifampin or isoniazid plus rifabutin: A phase I study

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Mar 2018

At a glance

  • Drugs CC 11050 (Primary) ; Isoniazid; Rifabutin; Rifampicin
  • Indications Cutaneous lupus erythematosus
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 28 Mar 2018 New trial record
    • 24 Mar 2018 Results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top